5.65
price down icon4.96%   -0.295
after-market Handel nachbörslich: 5.65
loading
Schlusskurs vom Vortag:
$5.945
Offen:
$5.645
24-Stunden-Volumen:
1.28M
Relative Volume:
1.01
Marktkapitalisierung:
$262.87M
Einnahmen:
$124.00K
Nettoeinkommen (Verlust:
$-49.99M
KGV:
-3.3432
EPS:
-1.69
Netto-Cashflow:
$-31.03M
1W Leistung:
-34.76%
1M Leistung:
-37.05%
6M Leistung:
-18.47%
1J Leistung:
+257.59%
1-Tages-Spanne:
Value
$5.43
$5.75
1-Wochen-Bereich:
Value
$5.43
$8.61
52-Wochen-Spanne:
Value
$1.56
$14.60

Candel Therapeutics Inc Stock (CADL) Company Profile

Name
Firmenname
Candel Therapeutics Inc
Name
Telefon
617-916-5445
Name
Adresse
117 KENDRICK STREET, NEEDHAM
Name
Mitarbeiter
38
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
CADL's Discussions on Twitter

Vergleichen Sie CADL mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CADL
Candel Therapeutics Inc
5.65 262.87M 124.00K -49.99M -31.03M -1.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-20 Eingeleitet Citigroup Buy
2025-02-19 Eingeleitet Canaccord Genuity Buy
2025-02-07 Eingeleitet BofA Securities Buy
2022-12-02 Eingeleitet H.C. Wainwright Buy
2021-11-19 Eingeleitet BMO Capital Markets Outperform
2021-08-23 Eingeleitet Credit Suisse Outperform
2021-08-23 Eingeleitet Jefferies Buy
2021-08-23 Eingeleitet UBS Buy
Alle ansehen

Candel Therapeutics Inc Aktie (CADL) Neueste Nachrichten

pulisher
Mar 29, 2025

Candel Therapeutics reports breakthrough data for late-stage lung cancer – ICYMI - Proactive financial news

Mar 29, 2025
pulisher
Mar 27, 2025

Candel Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:CADL - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Candel Therapeutics Shares Are Down Today: What's Going On? - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Candel Therapeutics shares positive survival data for investigational immunotherapy in NSCLC - Proactive financial news

Mar 27, 2025
pulisher
Mar 27, 2025

Candel Therapeutics Clinical Trial for CAN-2409 Demonstrates Promising Survival Extensions for NSCLC Patients Who Failed Previous Therapies - citybiz

Mar 27, 2025
pulisher
Mar 27, 2025

Candel Therapeutics Reports Positive Phase 2a Trial Results - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Trading (CADL) With Integrated Risk Controls - news.stocktradersdaily.com

Mar 27, 2025
pulisher
Mar 26, 2025

Candel Therapeutics Reports Final Phase 2a Survival Data for Lung Cancer Treatment - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

Candel Therapeutics reports positive survival data for CAN-2409 in advanced lung cancer trial - Proactive Investors UK

Mar 26, 2025
pulisher
Mar 26, 2025

Candel Therapeutics Reports Both Prolonged Median Overall Survival And Long Tail Of Survival In Phase 2A Clinical Trial Of CAN-2409 In Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive To Immune Checkpoint Inhibitor (ICI) Treat - Marketscreener.com

Mar 26, 2025
pulisher
Mar 26, 2025

Candel Therapeutics Reports Both Prolonged Median Overall - GlobeNewswire

Mar 26, 2025
pulisher
Mar 26, 2025

Breakthrough: Cancer Drug CAN-2409 Achieves 24.5-Month Survival in Advanced Lung Cancer Patients - Stock Titan

Mar 26, 2025
pulisher
Mar 26, 2025

Small cap wrap: Nano One Materials, EnWave, Summit Therapeutics... - Proactive financial news

Mar 26, 2025
pulisher
Mar 25, 2025

Bears are Losing Control Over Candel Therapeutics (CADL), Here's Why It's a 'Buy' Now - Zacks Investment Research

Mar 25, 2025
pulisher
Mar 21, 2025

CADLCandel Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan

Mar 21, 2025
pulisher
Mar 21, 2025

Candel therapeutics CEO sells $229,624 in stock By Investing.com - Investing.com Canada

Mar 21, 2025
pulisher
Mar 20, 2025

Candel therapeutics chief scientific officer sells $281,672 in stock By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

Candel Therapeutics’ chief medical officer sells $396,995 in stock By Investing.com - Investing.com Canada

Mar 20, 2025
pulisher
Mar 20, 2025

Candel Therapeutics’ chief medical officer sells $396,995 in stock - Investing.com India

Mar 20, 2025
pulisher
Mar 20, 2025

Candel Therapeutics Executives Sell Shares Under Trading Plans - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

Candel therapeutics CEO sells $229,624 in stock - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

Small cap wrap: Santacruz Silver, GoviEx Uranium, Candel Therapeutics... - Proactive Investors

Mar 20, 2025
pulisher
Mar 20, 2025

Candel Therapeutics Partners With IDEA Pharma To Advance CAN-2409 Cancer Immunotherapy - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

Candel Therapeutics partners with IDEA Pharma on commercialization of CAN-2409 - Proactive Investors

Mar 20, 2025
pulisher
Mar 20, 2025

Candel Therapeutics Partners With IDEA Pharma for CAN-2409 Commercialization -March 20, 2025 at 08:29 am EDT - Marketscreener.com

Mar 20, 2025
pulisher
Mar 20, 2025

Candel Therapeutics and IDEA Pharma Announce Strategic - GlobeNewswire

Mar 20, 2025
pulisher
Mar 20, 2025

Breakthrough Prostate Cancer Drug Shows 30% Better Results as Candel Secures Key Partnership - Stock Titan

Mar 20, 2025
pulisher
Mar 20, 2025

Candel therapeutics CFO Charles Schoch sells $44,169 in stock - Investing.com India

Mar 20, 2025
pulisher
Mar 19, 2025

Candel therapeutics CFO Charles Schoch sells $44,169 in stock By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Candel therapeutics CTO sells $275,947 worth of common stock By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Candel therapeutics CTO sells $275,947 worth of common stock - Investing.com

Mar 19, 2025
pulisher
Mar 18, 2025

Small cap wrap: Fineqia, Candel Therapeutics, Ocean Power Technologies, Protalix Biotherapeutics... - Proactive Investors UK

Mar 18, 2025
pulisher
Mar 18, 2025

Candel Therapeutics appoints cancer immunology expert to research advisory board - Proactive financial news

Mar 18, 2025
pulisher
Mar 18, 2025

Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board - The Manila Times

Mar 18, 2025
pulisher
Mar 18, 2025

Candel Therapeutics Appoints Renowned Pancreatic Cancer - GlobeNewswire

Mar 18, 2025
pulisher
Mar 18, 2025

Top Pancreatic Cancer Expert Joins Candel Therapeutics Following Promising Trial Results - StockTitan

Mar 18, 2025
pulisher
Mar 17, 2025

H.C. Wainwright maintains Buy on Candel Therapeutics stock By Investing.com - Investing.com Canada

Mar 17, 2025
pulisher
Mar 17, 2025

H.C. Wainwright maintains Buy on Candel Therapeutics stock - Investing.com India

Mar 17, 2025
pulisher
Mar 16, 2025

When (CADL) Moves Investors should Listen - Stock Traders Daily

Mar 16, 2025
pulisher
Mar 15, 2025

Candel Therapeutics Reports Positive Clinical Trial Results - TipRanks

Mar 15, 2025
pulisher
Mar 14, 2025

Candel Therapeutics (CADL) Receives a Buy from Bank of America Securities - The Globe and Mail

Mar 14, 2025
pulisher
Mar 13, 2025

Candel Therapeutics eyes CAN-2409 BLA filing, advances cancer pipeline - Proactive financial news

Mar 13, 2025
pulisher
Mar 13, 2025

Candel Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 13, 2025
pulisher
Mar 13, 2025

Candel Therapeutics Reports Positive Data from Multiple Clinical Trials and Outlines Plans for CAN-2409 and CAN-3110 - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire

Mar 13, 2025
pulisher
Mar 13, 2025

Candel's Breakthrough: Phase 3 Trial Shows 30% Cancer Risk Reduction, Extends Survival 2.5x - StockTitan

Mar 13, 2025
pulisher
Mar 13, 2025

Small cap wrap: Fineqia, Ocean Power Technologies, NEXE Innovations... - Proactive Investors UK

Mar 13, 2025
pulisher
Mar 11, 2025

Candel Therapeutics, Inc. (NASDAQ:CADL) Shares Acquired by Rhumbline Advisers - Defense World

Mar 11, 2025
pulisher
Mar 08, 2025

Oppenheimer & Co. Inc. Purchases Shares of 37,915 Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World

Mar 08, 2025
pulisher
Mar 06, 2025

(CADL) Technical Data - Stock Traders Daily

Mar 06, 2025

Finanzdaten der Candel Therapeutics Inc-Aktie (CADL)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Kapitalisierung:     |  Volumen (24h):